

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Boulding Mark Elliott</u> (Last) (First) (Middle) C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT (Street) SOUTH PLAINFIELD NJ 07080 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>PTC THERAPEUTICS, INC. [PTCT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ Officer (give title below) <input checked="" type="checkbox"/> Exec. VP and CLO 10% Owner _____ Other (specify below) _____
	3. Date of Earliest Transaction (Month/Day/Year) 02/10/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/10/2022		M ⁽¹⁾		2,282	A	\$11.23	63,392	D	
Common Stock	02/10/2022		S ⁽¹⁾		2,282	D	\$45.027 ⁽²⁾	61,110	D	
Common Stock	02/10/2022		M ⁽¹⁾		15,653	A	\$18.01	76,763	D	
Common Stock	02/10/2022		S ⁽¹⁾		15,653	D	\$45.027 ⁽²⁾	61,110	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$11.23	02/10/2022		M ⁽¹⁾			2,282	(3)	01/02/2027	Common Stock	2,282	\$11.23	2,281	D	
Stock Option (Right to Buy)	\$18.01	02/10/2022		M ⁽¹⁾			15,653	(3)	01/02/2028	Common Stock	15,653	\$18.01	0	D	
Stock Option (Right To Buy)	\$51							(3)	01/01/2025	Common Stock	85,600		85,600	D	
Stock Option (Right To Buy)	\$30.86							(3)	01/03/2026	Common Stock	70,000		70,000	D	
Stock Option (Right To Buy)	\$33.02							(4)	01/21/2029	Common Stock	72,500		72,500	D	
Stock Option (Right To Buy)	\$33.02							(5)	01/21/2029	Common Stock	17,500		17,500	D	
Stock Option (Right To Buy)	\$51.16							(6)	01/28/2030	Common Stock	59,500		59,500	D	
Stock Option (Right to Buy)	\$66.49							(7)	01/05/2031	Common Stock	59,500		59,500	D	
Stock Option (Right to Buy)	\$38.1							(8)	01/06/2032	Common Stock	54,000		54,000	D	

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021.
2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$45.01 to \$45.04 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. Currently exercisable.
4. This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
5. This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
6. This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
7. This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
8. This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.

Remarks:

/s/ Avraham S. Adler, attorney-
in-fact 02/11/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.